Neurocrine Biosciences (NBIX) Total Non-Current Liabilities (2010 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Total Non-Current Liabilities of $1.4 billion for Q2 2026, up 38.81% year-over-year from $985.4 million in Q2 2025, and up 10.49% on a QoQ basis from $1.2 billion in Q1 2026.
Neurocrine Biosciences (NBIX) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Total Non-Current Liabilities for 17 years, with the latest figure at $1.4 billion in Q2 2026.
- Total Non-Current Liabilities for Q2 2026 came in at $1.4 billion, up 38.81% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 38.81% YoY), and the FY2025 annual result was $1.2 billion, up 20.35% from the prior year.
- Total Non-Current Liabilities grew to $1.4 billion in Q2 2026, from $1.2 billion in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $1.4 billion in Q2 2026 and troughed at $554.3 million in Q2 2022.
- A 5-year average of $863.8 million and a median of $845.3 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities dropped 14.49%; it then soared 56.57% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $631.2 million in 2022, then surged by 44.66% to $913.1 million in 2023, then climbed by 5.44% to $962.8 million in 2024, then advanced by 20.35% to $1.2 billion in 2025, then increased by 18.05% to $1.4 billion in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $1.4 billion in Q2 2026, $1.2 billion in Q1 2026, and $1.2 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 334.00 Mn |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 2.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.37 Bn |
| Mar 31, 2026 | 1.24 Bn |
| Dec 31, 2025 | 1.16 Bn |
| Sep 30, 2025 | 1.07 Bn |
| Jun 30, 2025 | 985.40 Mn |
| Mar 31, 2025 | 970.40 Mn |
| Dec 31, 2024 | 962.80 Mn |
| Sep 30, 2024 | 681.10 Mn |
| Jun 30, 2024 | 654.70 Mn |
| Mar 31, 2024 | 965.80 Mn |
| Dec 31, 2023 | 913.10 Mn |
| Sep 30, 2023 | 777.50 Mn |
| Jun 30, 2023 | 671.60 Mn |
| Mar 31, 2023 | 634.00 Mn |
| Dec 31, 2022 | 631.20 Mn |
| Sep 30, 2022 | 581.70 Mn |
| Jun 30, 2022 | 554.30 Mn |
| Mar 31, 2022 | 733.70 Mn |
| Dec 31, 2021 | 686.20 Mn |
| Sep 30, 2021 | 663.00 Mn |